Healthcare private equity transactions under scrutiny: Midyear review

Healthcare private equity transactions under scrutiny: Midyear review 
Healthcare Business Today; by Editorial Team; 9/4/24 
Highlights

• Holland & Knight predicted last year that the “the current enforcement environment will continue into 2024 and will focus heavily on the healthcare industry, along with private equity transactions or ‘roll-ups.'”
• At the macro level, the first half of 2024 saw two U.S. senators propose bills attempting to regulate private equity’s involvement in the healthcare industry while the U.S. Federal Trade Commission aggressively targeted private equity for its role in healthcare. There was also an influx of new state legislation, including efforts to directly restrict private equity investment, but many efforts failed to pass this legislative term.
• This Holland & Knight alert provides a midyear review of the ongoing federal and state scrutiny focused on private equity investments in the healthcare industry and what investors and platform companies can expect for the rest of the year.

Publisher's note: This article includes state-specific information on IN, CA, PA, CT, MA, MN, OR, and WA.